1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Illinois Tool Works entered into an amendment to its Euro-denominated credit agreement with ING Bank, N.V., London Branch, as agent, on February 24, 2025. The amendment extends the termination date to February 28, 2027, with an option to extend to September 15, 2027, and lowers the interest rate spread on loans from 0.75% to 0.70%. The company's facility is fully drawn, so the change affects the cost and term of existing borrowing rather than adding available capacity.
Amendment dated February 24, 2025, to the Euro credit agreement originally dated May 5, 2023
Termination date extended to February 28, 2027; company may extend to September 15, 2027 under stated conditions
Interest rate spread on loans decreased from 0.75% to 0.70%
€750 million outstanding; facility fully drawn with no amounts available for additional borrowing
Targa Resources Corp. completed a $2.0 billion underwritten offering of senior notes due 2035 and 2055, each $1.0 billion. The company expects to use part of the proceeds to repurchase the outstanding preferred equity in Targa Badlands LLC, which holds its North Dakota assets, for about $1.8 billion in cash. For shareholders, this is a large debt-funded transaction that adds long-term borrowing while buying out a joint venture partner's stake.
$1.0 billion of 5.550% Senior Notes due 2035 and $1.0 billion of 6.125% Senior Notes due 2055 were issued on February 27, 2025.
Proceeds are expected to fund a roughly $1.8 billion cash repurchase of joint venture partner's preferred equity in Targa Badlands LLC, expected to close in the first quarter of 2025.
If the Badlands transaction does not close, proceeds will go to general corporate purposes, including repaying commercial paper borrowings.
Astrana Health entered an amended and restated credit agreement on February 26, 2025, with Truist Bank as agent and a group of lenders. The facilities total $1.295 billion, including a $745 million delayed draw term loan to finance an acquisition under a November 8, 2024 purchase agreement with Prospect Medical Holdings. The new debt terms replace the company's 2021 credit agreement and carry leverage and interest coverage covenants, plus a security interest in the company's assets.
Revolving credit facility of $300 million, term loan A of $250 million and delayed draw term loan of $745 million, all five-year facilities
Delayed draw term loan funds an asset and equity acquisition from Prospect Medical Holdings, Inc. under an agreement dated November 8, 2024
Interest rate spreads of 1.25% to 2.50% over term SOFR, set quarterly by leverage ratio; covenants require maximum net leverage of 5.00 to 1.00, stepping down to 4.50 to 1.00 after March 31, 2027, and minimum interest coverage of 2.50 to 1.
Separate 2025 Annual Meeting of Stockholders set for June 11, 2025, held virtually, with a record date of April 22, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.